Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage gene editing company that regularly issues news and updates about its in vivo CRISPR-based pipeline. Company announcements emphasize the development of transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 systems, proprietary targeted lipid nanoparticle delivery, and a differentiated gene upregulation strategy applied to serious diseases.
News about Editas Medicine frequently covers progress with its lead in vivo development candidate, EDIT-401, an LDLR-targeted gene editing medicine designed to treat hyperlipidemia by increasing LDL receptor expression and reducing LDL cholesterol (LDL-C) levels. Recent releases have described preclinical proof-of-concept data in non-human primates and mice, showing approximately 90% or greater reductions in LDL-C after a single dose, as well as presentations at major scientific meetings such as the European Society of Gene and Cell Therapy Congress and the American Heart Association Scientific Sessions.
Investors and followers of EDIT can also expect updates on Editas’ in vivo hematopoietic stem cell program for sickle cell disease and beta thalassemia, including data on HBG1/2 promoter editing, fetal hemoglobin upregulation, and targeted lipid nanoparticle delivery in humanized mice and non-human primates. Additional news items highlight in vivo proof-of-concept for undisclosed liver targets, conference presentations at ASGCT, EHA, and TIDES, and participation in healthcare and investor conferences.
Financial news from Editas Medicine includes quarterly results, collaboration milestones such as the CD19 HD allogeneic CAR T program with Bristol Myers Squibb, and updates on cash runway supported by cash, marketable securities, at-the-market equity proceeds, and payments under its license agreement with Vertex Pharmaceuticals. This news page helps readers follow how scientific data, regulatory plans, collaborations, and financial developments shape the EDIT investment story over time.
On October 1, 2020, Editas Medicine (Nasdaq: EDIT) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference, scheduled for October 5, 2020, at 10:30 a.m. ET. The event will feature a fireside chat and will be webcast live on the company's website, with archived recordings available for 30 days post-event. Editas Medicine focuses on developing transformative genomic medicines using CRISPR technology to treat serious diseases. For more updates, visit www.editasmedicine.com.
Editas Medicine, Inc. (Nasdaq: EDIT) announced that the U.S. Patent and Trademark Office has granted Broad Institute’s motion for priority in a patent interference case. This decision denies priority to CVC, meaning Broad is now the 'Senior Party.' Editas remains confident in its exclusive licenses for foundational CRISPR/Cas9 patents. Broad’s patents are valid in multiple jurisdictions, including the U.S., and Editas aims to leverage these innovations in developing treatments for serious diseases.
Editas Medicine, a leading genome editing company, will participate in several upcoming investor conferences. Key events include Citi’s 15th Annual BioPharma Virtual Conference on September 9, 2020, at 3:20 p.m. ET, a fireside chat at the Wells Fargo 2020 Virtual Healthcare Conference on September 10, 2020, at 10:40 a.m. ET, and another fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 10:15 a.m. ET. These events will be webcast live on the company’s website, with recordings available for 30 days afterwards.
Editas Medicine has regained full control of ocular medicines with a new agreement with AbbVie. The company is on track to dose patients in the BRILLIANCE trial for EDIT-101 by the end of 2020, and plans to file an IND for EDIT-301 for sickle cell disease. A recent equity offering raised $216 million, strengthening its balance sheet, which now holds $599 million in cash as of June 30, 2020. The company reported a net loss of $23.6 million for Q2 2020, an improvement from $33.8 million in Q2 2019, with an increase in collaboration revenues to $10.7 million.
Editas Medicine has regained full global rights to develop and commercialize ocular medicines, including EDIT-101 for Leber congenital amaurosis 10, after terminating a previous alliance with Allergan, now part of AbbVie. CEO Cynthia Collins expressed optimism about advancing EDIT-101, with dosing resuming in the Phase 1/2 BRILLIANCE trial. They aim to complete dosing of the adult low-dose cohort and dose adult mid-dose patients by year-end. J.P. Morgan Securities LLC is advising Editas on this transition.
Editas Medicine (Nasdaq: EDIT) has partnered with Catalent to enhance the development and manufacturing of its in vivo CRISPR medicines and engineered cell therapies. Catalent will support Editas with clinical supply and production from its facilities in Maryland and Texas, ensuring efficient delivery to clinical trial sites. This collaboration aims to leverage Catalent's advanced technologies to expedite Editas' innovative therapies, potentially improving patient access to new treatments.
Editas Medicine has appointed Gad Berdugo as the new Chief Business Officer, effective immediately. Berdugo brings over 25 years of experience in biotech corporate development and business strategy. He previously held executive roles at EpiVax Oncology and Immune Pharmaceuticals. Under his leadership, Editas aims to enhance its business development and advance its clinical and preclinical pipeline, which includes ongoing trials and strategic partnerships. President Cynthia Collins expressed confidence in Berdugo's ability to drive the company’s growth amidst the dynamic gene editing landscape.
Editas Medicine, a leader in genome editing, will host a conference call on August 6, 2020, at 5:00 p.m. ET to discuss its corporate updates and Q2 2020 results. Participants can join the call by dialing 844-348-3801 (domestic) or 213-358-0955 (international) and using passcode 9185596. A live webcast will also be available on their website. Editas focuses on leveraging CRISPR technology to develop transformative genomic treatments for serious diseases worldwide.
On June 26, 2020, Editas Medicine (Nasdaq: EDIT) announced the completion of its underwritten public offering, selling 6,900,000 shares of common stock at a price of $31.25 per share. The offering generated approximately $215.6 million in gross proceeds, which includes 900,000 shares sold due to underwriter options. The registration statement related to the offering has been filed and is effective with the SEC. Morgan Stanley acted as the sole book-running manager for this offering.
Editas Medicine has announced an underwritten offering of 6,000,000 shares of its common stock at a price of $31.25 per share, aiming for gross proceeds of approximately $187.5 million. The offering features a 30-day option for underwriters to purchase an additional 900,000 shares. Scheduled to close around June 26, 2020, this transaction is being managed by Morgan Stanley and follows a Form S-3 registration with the SEC.
FAQ
What is the current stock price of Editas Medicine (EDIT)?
What is the market cap of Editas Medicine (EDIT)?
